Negative symptoms in Schizophrenia: Neurobiological models and treatment response

Harvard Review of Psychiatry

Volumn 6, Issue 2, 1998, Pages 59-77

  Goff, Donald C ^a   Evins, A Eden ^b  

^a Freedom Trail Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DEXAMPHETAMINE; EXCITATORY AMINO ACID RECEPTOR; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GLYCINE; HALOPERIDOL; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; RITANSERIN; SELEGILINE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; TRIFLUOPERAZINE;

CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; NEGATIVE SYNDROME; NEUROMODULATION; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; SYNDROME DELINEATION;

EID: 0031858096     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229809000313     Document Type: Review

References (208)

1. Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: Livingstone, 1919.
2. Jackson JH. Remarks on the evolution and dissolution of the nervous system. J Ment Sci 1904;33:25-48.
3. Bleuler E. Dementia praecox or the group of schizophrenias. New York: International Universities Press, 1950.
4. Kendell RE, Cooper JE, Gourlay AG, Copeland JR, Sharpe L, Gurland BJ. Diagnostic criteria of American and British psychiatrists. Arch Gen Psychiatry 1971;25:123-30.
5. Andreasen NC, Grove WM, Shapiro RW, Keller MB, Hirschfeld RM, McDonald-Scott P. Reliability of lifetime diagnosis: a multicenter collaborative perspective. Arch Gen Psychiatry 1981;38:400-5.
6. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980;137:383-6.
7. Andreasen NC, Olsen S. Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982;39: 789-94.
8. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982;39:784-8.
9. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980;280:66-8.
10. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricle size and cognitive impairment in chronic schizophrenia. Lancet 1976;2:924-6.
11. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1:848-51.
12. Crow TJ. The two-syndrome concept: origins and current status. Schizophr Bull 1985;11:471-86.
13. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1981.
14. Andreasen NC, Olsen SA, Dennert JW, Smith MR. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry 1982;139:297-302.
15. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia: prediction and patterns of change. Arch Gen Psychiatry 1995;52:352-60.
16. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings and mechanisms. Arch Gen Psychiatry 1995;52:341-51.
17. Liddle PF. The symptoms of chronic schizophrenia: a reexamination of the positive-negative dichotomy. Br J Psychiatry 1987;151:145-51.
18. Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC, et al. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the Brief Psychiatric Rating Scale. Biol Psychiatry 1996;40:755-60.
19. Möller HJ. The negative component in schizophrenia. Acta Psychiatr Scand 1995;91(suppl 388):11-4.
20. Sommers AA. "Negative symptoms": conceptual and methodological problems. Schizophr Bull 1985;11:364-79.
21. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988;23:99-110.
22. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS). Psychol Rep 1962;10:799-812.
23. Alphs LD, Summerfelt A, Lann H, Muller RJ. The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989;25: 159-63.
24. Iager AC, Kirch DG, Wyatt RJ. A negative symptom rating scale. Psychiatry Res 1985;16:27-36.
25. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30:119-23.
26. Peralta V, De Leon J, Cuesta MJ. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry 1992;161:335-43.
27. Peralta V, Cuesta MJ. Symptoms of the schizophrenic negative syndrome. Br J Psychiatry 1996;169:209-12.
28. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-83.
29. Möller HJ, Van Praag HM, Aufdembrinke B, Bailey P, Barnes TRE, Beck J, et al. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology 1994;115:221-8.
30. Van Putten T, May PRA. "Akinetic depression" in schizophrenia. Arch Gen Psychiatry 1978;35:1101-7.
31. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025-9.
32. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 1986;47(5, suppl):30-3.
33. Harvey PD, Putnam KM, Davidson M, Kahn RS, Powchik P, McQueeney R, et al. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res 1991;38: 285-92.
34. Miller DD, Flaum M, Arndt S, Fleming F, Andreasen NC. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 1994;11:11-20.
35. Kuck J, Zisook S, Moranville JT, Heaton RK, Braff DL. Negative symptomatology in schizophrenic outpatients. J Nerv Ment Dis 1992;180:510-5.
36. Kulhara P, Avasthi A, Chadda R, Chandiramani K, Mattoo SK, Kota SK, et al. Negative and depressive symptoms in schizophrenia. Br J Psychiatry 1989;154:207-11.
37. Pogue-Geile MF, Harrow M. Negative and positive symptoms in schizophrenia and depression: a followup. Schizophr Bull 1984;10:371-87.
38. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 1988;145: 1532-7.
39. Newcomer JW, Faustman WO, Yeh W, Csernansky JG. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res 1990;31: 243-50.
40. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991;17:75-98.
41. Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440-52.
42. Fenton WS, McGlashan TH. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992;49:179-84.
43. Kirkpatrick B, Buchanan RW. The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 1990;178: 545-55.
44. Scoville WB, Dunsmore RH, Liberson WT, Henry CE, Pepe A. Observations on medial temporal lobotomy and uncotomy in the treatment of psychotic states: preliminary review of 19 operative cases compared with 60 frontal lobotomy and undercutting cases. Res Publ Assoc Res Nerv Ment Dis 1953;31:347-73.
45. Blumer D, Benson DF. Personality changes with frontal and temporal lobe lesions. In: Blumer D, Benson DF, eds. Psychiatric aspects of neurological disease. New York: Grune & Stratton, 1975:151-70.
46. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873-80.
47. Damasio AR, Van Hoesen GW. Emotional disturbances associated with focal lesions of the limbic frontal lobe. In: Heilman KM, Satz P, eds. Neuropsychology of human emotion. New York: Guilford, 1983:85-110.
48. Ballantine HT Jr, Bouckoms AJ, Thomas EK, Giriunas IE. Treatment of psychiatric illness by stereotactic cingulotomy. Biol Psychiatry 1987;22:807-19.
49. Andreasen NC, Flaum M, Swayze VW II, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia: a critical reappraisal. Arch Gen Psychiatry 1990;47:615-21.
50. Young AH, Blackwood DHR, Roxborough H, McQueen JK, Martin MJ, Kean D. A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms. Br J Psychiatry 1991;158:158-64.
51. Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE. Frontal and temporal lobe brain volumes in schizophrenia: relationship to symptoms and clinical subtype. Arch Gen Psychiatry 1995;52:1061-70.
52. Andreasen NC, Rezai K, Alliger R, Swayze VW II, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943-58.
53. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992;160:179-86.
54. Volkow ND, Wolf AP, Van Gelder P, Brodie JD, Overall JE, Cancro R, et al. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry 1987;144:151-8.
55. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992;49:959-65.
56. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-30.
57. Schröder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, et al. Cerebral metabolic activity correlates of sub-syndromes in chronic schizophrenia. Schizophr Res 1996; 19:41-53.
58. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, et al. Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 1993;11:47-54.
59. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 1986;43: 114-25.
60. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, II: a new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609-15.
61. Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT Jr. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry 1994;51:804-11.
62. Norman RMG, Malla AK, Morrison-Stewart SL, Helmes E, Williamson PC, Thomas J, et al. Neuropsychological correlates of syndromes in schizophrenia. Br J Psychiatry 1997; 170:134-9.
63. Braff DL. Sensory input deficits and negative symptoms in schizophrenic patients. Am J Psychiatry 1989;146:1006-11.
64. Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT Jr. Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry 1997;154:363-70.
65. Liddle PF, Morris DL. Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry 1991;158:340-5.
66. Morrison-Stewart SL, Williamson PC, Corning WC, Kutcher SP, Snow WG, Merskey H. Frontal and non-frontal lobe neuropsychological test performance and clinical symptomatology in schizophrenia. Psychol Med 1992;22:353-9.
67. Machiyama Y. Chronic methamphetamine intoxication model of schizophrenia in animals. Schizophr Bull 1992;18: 107-13.
68. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86.
69. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980;286:74-6.
70. Deutch AY. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992;36:61-89.
71. Lipska BK, Jaskiw GE, Braun AR, Weinberger DR. Prefrontal cortical and hippocampal modulation of haloperidolinduced catalepsy in apomorphine-induced stereotypic behaviors in the rat. Biol Psychiatry 1995;38:255-62.
72. Bowers MB Jr. Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry 1974;31:50-4.
73. Van Kammen DP, Van Kammen WB, Mann LS, Seppala T, Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 1986;43:978-83.
74. Lindström LH. Low HVA and normal CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Res 1985;14:265-73.
75. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 1984;225:954-7.
76. Suzuki E, Kanba S, Nibuya M, Adachi S, Sekiya U, Shintani F, et al. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. Biol Psychiatry 1994;36:654-61.
77. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 1986;43:669-76.
78. Petrie EC, Faustman WO, Moses JA, Lombrozo L, Csernansky JG. Correlates of rapid neuroleptic response in male patients with schizophrenia. Psychiatry Res 1990;33:171-7.
79. Daniel DG, Berman KF, Weinberger DR. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J Neuropsychiatry Clin Neurosci 1989;1:377-84.
80. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991;11:1907-17.
81. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE. Cognitive and behavioral effects of the co-administration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 1991;148:78-84.
82. Wolkin A, Angrist B, Wolf A, Brodie J, Wolkin B, Jaeger J, et al. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology 1987;92:241-6.
83. 2 receptors and negative symptoms of schizophrenia. Br J Psychiatry 1994; 164:27-34.
84. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990;147:719-24.
85. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
86. Sawaguchi T, Matsumura M, Kubota K Catecholaminergic effects on neuronal activity related to a delayed response task in monkey prefrontal cortex. J Neurophysiol 1990;63: 1385-400.
87. 1-adrenoreceptor antagonism. J Clin Psychopharmacol 1995;15(1, suppl 1):11-8S.
88. 2 antagonist ritanserin blocks the effect of pre-frontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol Scand 1989;136:497-8.
89. Grenhoff J, Nisell M, Ferré S, Aston-Jones G, Svensson TH. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm 1993;93:11-25.
90. Withers NW, Pulvirenti L, Koob GF, Gillin JC. Cocaine abuse and dependence. J Clin Psychopharmacol 1995;15:63-78.
91. Pulvirenti L, Maldonado-Lopez R, Koob GF. NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res 1992; 594:327-30.
92. Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993;260: 1814-6.
93. Roberts DCS, Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioural screen for antipsychotic activity. Psychopharmacology 1984;82:135-9.
94. Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 1994;182:109-12.
95. Serper MR, Alpert M, Richardson NA, Dickson S, Allen MH, Werner A. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry 1995; 152:1464-9.
96. Serper MR, Alpert M, Trujillo M. Recent cocaine use decreases negative signs in acute schizophrenia: a case study over two consecutive admissions. Biol Psychiatry 1996;39: 816-8.
97. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989;46:745-53.
98. Tandon R, Greden JF, Silk KR. Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 1988;8:212-5.
99. Tandon R, Mann NA, Eisner WH, Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1990; 31:235-41.
100. Goff DC, Arana GW, Greenblatt DJ, Dupont R, Ornsteen M, Harmatz JS, et al. The effect of benztropine on haloperidolinduced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991;11:106-12.
101. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993;13:57-67.
102. Goff DC, Amico E, Dreyfuss D, Ciraulo D. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psychiatry 1994;151:429-31.
103. Garelis E, Gillen JC, Wyatt RJ, Neff N. Elevated blood serotonin concentrations in unmedicated chronic schizophrenic patients: a preliminary study. Am J Psychiatry 1975;132: 184-6.
104. Freedman DX, Belendiuk K, Belendiuk GW, Crayton JW. Blood tryptophan metabolism in chronic schizophrenics. Arch Gen Psychiatry 1981;38:655-9.
105. DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ. Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 1981;38: 647-50.
106. Jackman H, Luchins D, Meltzer HY. Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. Biol Psychiatry 1983;18:887-902.
107. Stahl SM, Woo DJ, Mefford IN, Berger PA, Ciaranello RD. Hyperserotonemia and platelet serotonin uptake in schizophrenia and affective disorders. Am J Psychiatry 1983; 140:26-30.
108. Csernansky JG, King RJ, Faustman WO, Moses JA Jr, Poscher ME, Faull KF. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. Br J Psychiatry 1990; 156:501-7.
109. Bleich A, Brown SL, Kahn R, Van Praag HM. The role of serotonin in schizophrenia. Schizophr Bull 1988;14:297-315.
110. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 1993;112(1, suppl):S35-9.
111. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
112. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.
113. Kalivas PW, Duffy P, Barrow J. Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J Pharmacol Exp Ther 1989;251:378-87.
114. Carpenter WT Jr. The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 1996;168(suppl 29):17-22.
115. Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand 1994;89(suppl 380):21-6.
116. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Sooley S, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52:29-41.
117. Silver H, Geraisy N. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients. Biol Psychiatry 1995;38:413-5.
118. Scidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993;33:575-84.
119. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992;31:698-704.
120. Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985;11: 453-6.
121. Kay SR, Singh MM. The positive-negative distinction in drug-free schizophrenic patients: stability, response to neuroleptics, and prognostic significance. Arch Gen Psychiatry 1989;46:711-8.
122. Serban G, Siegel S, Gaffney M. Response of negative symptoms of schizophrenia to neuroleptic treatment. J Clin Psychiatry 1992;53:229-34.
123. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, et al. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987; 144:1549-55.
124. Tandon R, Goldman RS, Goodson J, Greden JF. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiatry 1990;27:1323-6.
125. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27:341-7.
126. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-8.
127. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:518-21.
128. Van Kammen DP, Peters J, Yao J, Van Kammen WB, Neylan T, Shaw D, et al. Norepinephrine in acute exacerbations of chronic schizophrenia: negative symptoms revisited. Arch Gen Psychiatry 1990;47:161-8.
129. Bustillo JR, Kirkpatrick B, Buchanan RW. Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia. Biol Psychiatry 1995;38:64-7.
130. Volavka J, Cooper TB, Czobor P, Meisner M. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacol Bull 1996;32:75-9.
131. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
132. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152:827-32.
133. Meltzer HY. Clozapine: is another view valid? Am J Psychiatry 1995;152:821-5.
134. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994;35:8-15.
135. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-52.
136. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994:151:20-6.
137. Conley R, Richardson C, Kent D, Gounaris C, Zaremba S. Clozapine response varies in deficit vs non-deficit schizophrenic subjects [Abstract]. Biol Psychiatry 1994;35:746.
138. Kane JM, Safferman AZ, Pollack S, Johns C, Szymanski S, Kronig M, et al. Clozapine, negative symptoms, and extrapyramidal side effects. J Clin Psychiatry 1994;55(suppl B): 74-7.
139. Youngren KD, Moghaddam B, Bunney BS, Roth RH. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 1994; 165:41-4.
140. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, et al. Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995;120:67-74.
141. i values. J Pharmacol Exp Ther 1989;251:238-46.
142. 2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993;163:451-5.
143. 2 blocker. Drug Dev Res 1986;8: 205-11.
144. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
145. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
146. Marder SR, Davis JM, Chouinard G. the effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46.
147. Goff DC. Have the serotonin-dopamine antagonists rendered traditional antipsychotic agents obsolete? Harvard Rev Psychiatry 1995;3:101-3.
148. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
149. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
150. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
151. Peuskens J, Link C. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
152. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91.
153. Van Kammen DP, Boronow JJ. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 1988;3:111-21.
154. Mathew RJ, Wilson WH. Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology 1989;21:117-23.
155. Sanfilipo M, Wolkin A, Angrist B, Van Kammen DP, Duncan E, Wieland S, et al. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology 1996;123:211-4.
156. Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM Jr. Combined drug therapy of chronic schizophrenics: controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. Am J Psychiatry 1961;117:997-1003.
157. Gerlach J, Luhdorf K The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double blind cross-over trial with Madopar and placebo. Psychopharmacologia 1975;44:105-10.
158. Chouinard G, Annable L, Mercier P, Turnier L. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987;23:221-6.
159. Inanaga K, Nakazawa Y, Inoue K, Tachibana H, Oshima M. Double-blind controlled study of L-dopa therapy in schizophrenia. Folia Psychiatr Neurol 1975;29:123-43.
160. Evins AE, Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 1996;6:130-47.
161. Siris SG, Mason SE, Bermanzohn PC, Alvir JM, McCorry TA. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol Bull 1990; 26:91-4.
162. Siris SG, Bermanzohn PC, Gonzalez A, Mason SE, White CV, Shuwall MA. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 1991;27:331-5.
163. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9:281-5.
164. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117:417-23.
165. Salokangas RKR, Saarijärvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996;94:175-80.
166. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996;153:1625-7.
167. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 1991;148:790-2.
168. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153: 466-76.
169. Stanford SC. Prozac: panacea or puzzle. Trends Pharmacol Sci 1996;17:150-4.
170. Perenyi A, Goswami U, Frecska E, Arato M, Bela A. L-Deprenyl in treating negative symptoms of schizophrenia [Letter]. Psychiatry Res 1992;42:189-91.
171. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication: a pilot study examining the role of dopamine. J Nerv Ment Dis 1996;184:295-301.
172. Bucci L. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 1987; 91:104-8.
173. Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA, et al. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 1993;33:700-6.
174. Collins AD, Dundas J. A double-blind trial of amitriptyline/ perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. Br J Psychiatry 1967;113: 1425-9.
175. Goff DC, Baldessarini RJ. Antipsychotics. In: Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W, eds. Drug interactions in psychiatry. 2nd ed. Baltimore: Williams & Wilkins, 1995:129-74.
176. Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P. Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Community Psychiatry 1994;45:1220-3.
177. Yamagami S, Soejima K Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia. Drugs Exp Clin Res 1989;4:171-6.
178. Geller E, Ritvo ER, Freeman BJ, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307:165-9.
179. Ritvo ER, Freeman BJ, Geller E, Yuwiler A. Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Psychiatry 1983;22:549-58.
180. Shore D, Korpi ER, Bigelow LB, Zee RF, Wyatt RJ. Fenfluramine and chronic schizophrenia. Biol Psychiatry 1985; 20:349-52.
181. Stahl SM, Uhr SB, Berger PA. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Biol Psychiatry 1985;20:1098-102.
182. Alphs LD, Lafferman JA, Ross L, Bland W, Levine J. Fenfluramine treatment of negative symptoms in older schizophrenic inpatients. Psychopharmacol Bull 1989;25:149-53.
183. Marshall BD Jr, Glynn SM, Midha KK, Hubbard JW, Bowen LL, Banzett L, et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 1989;9:110-5.
184. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993;19:371-429.
185. Freedman R, Kirch D, Bell J, Adler LE, Pecevich M, Pachtman E, et al. Clonidine treatment of schizophrenia: double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr Scand 1982;65:35-45.
186. Maas JW, Miller AL, Tekell JL, Funderburg L, Silva JA, True J, et al. Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. J Clin Psychopharmacol 1995;15:361-4.
187. Ko GN, Bigelow LB, Karoum F, Wyatt RJ. Acute clonidine in schizophrenia [Abstract]. Proc Am Psychiatr Assoc 1983: NR117.
188. Van Kammen DP, Peters JL, Van Kammen WB, Rosen J, Yao JK, McAdam D, et al. Clonidine treatment of schizophrenia: can we predict treatment response? Psychiatry Res 1989;27:297-311.
189. 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol 1993;13:264-7.
190. Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 1996;168:571-9.
191. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13:513-27.
192. Gerlach J, Rasmussen PT, Hansen L, Kristjansen P. Antiparkinsonian agents and long-term neuroleptic treatment: effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. Acta Psychiatr Scand 1977;55:251-60.
193. Chien CP, Castaldo V, Thornton A, Maltbie A. Prophylactic usage of antiparkinsonian drugs for akinesia. Psychopharmacol Bull 1979;15:75-8.
194. Hanlon TE, Schoenrich C, Freinek W, Turek I, Kurland AA. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologia 1966;9: 328-39.
195. Simpson GM, Cooper TB, Bark N, Sud I, Lee JH. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch Gen Psychiatry 1980;37:205-8.
196. Gardos G, Cole JO, Rapkin RM, LaBrie RA, Baquelod E, Moore P, et al. Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41:1030-5.
197. Tandon R, Dequardo JR. Treatment of schizophrenia with anticholinergic medications [Letter]. Am J Psychiatry 1995; 152:814-5.
198. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-36.
199. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 1996;3:241-53.
200. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 1992;31:337-50.
201. D'Souza DC, Charney D, Krystal J. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev 1995;1:227-60.
202. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-6.
203. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996;169:610-7.
204. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-5.
205. Goff DC, Tsai G, Levitt J, Amico E, McCarley R. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics. Presented at the 35th annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1996.
206. Van Berckel BNM, Hijman R, Van der Linden JA, Westenberg HGM, Van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996;40:1298-1300.
207. Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI. D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol 1996;19:444-50.
208. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996;153:1628-30.